Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Synthetic Lethality Druggable Genome RNAi Screen Identifies Genes Mediating Sensitivity To Lenalidomide In Multiple Myeloma Including RSK2

Yuan Xiao Zhu, Ph.D., Laura Bruins, Chang-Xin Shi, Ph.D., Jessica Schmidt, Chris Sereduk, Mia Champion, Ph.D., Esteban Braggio, Ph.D., Holly Yin, Ph.D., A. Keith Stewart, MBChB

Blood (2013) 122 (21): 3084.

https://doi.org/10.1182/blood.V122.21.3084.3084

Published: 2013

Journal Articles

Development Of a 47 Gene Sequencing Panel For Common Mutations Present In Multiple Myeloma : Preliminary Results In 77 p53 Deleted Patients

K. Martin Kortuem, MD, Christian Langer, MD, Esteban Braggio, Ph.D., Scott Van Wier, Jan Egan, PhD, Laura Bruins, Jessica Schmidt, Lars Bullinger, MD, PhD, Miriam Kull, MD, Stefan Knop, MD, Hermann Einsele, MD, A. Keith Stewart, MBA, MB, CHB

Blood (2013) 122 (21): 4449.

https://doi.org/10.1182/blood.V122.21.4449.4449

Published: 2013

Journal Articles

Cereblon Binding IMiD Small Molecules Mediate Myeloma Cell Death Via IRF4

Yuan Xiao Zhu, Ph.D., Chang-Xin Shi, Ph.D., Laura Bruins, Klaus Martin Kortuem, MD, Jessica Schmidt, Xiu-Bao Chang, Ph.D., Esteban Braggio, Ph.D., Leif Bergsagel, M.D., Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 1807.

https://doi.org/10.1182/blood.V120.21.1807.1807

Published: 2012

Journal Articles

Genome Wide Studies in Multiple Myeloma Identify XPO1/CRM-1 As a Critical Target Validated Using the Selective Inhibitor of Nuclear Export (SINE) KPT-276

Jessica Schmidt, Esteban Braggio, Ph.D., Marta Chesi, PhD, Jan Egan, PhD, Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Stephen Palmer, Victoria Garbitt, Dilara McCauley, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD, PhD, Leif Bergsagel, MD, Keith Stewart, MD

Blood (2012) 120 (21): 573.

https://doi.org/10.1182/blood.V120.21.573.573

Published: 2012

Journal Articles

Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma

Blood (2012) 120 (21): 194.

https://doi.org/10.1182/blood.V120.21.194.194

Published: 2012

Journal Articles

The Myeloma Genome in Drug Refractory Extra-Medullary Disease Identifies Mutations in Proteasome, Cereblon and Glucocorticoid Pathways

Jan Egan, PhD, Klaus Martin Kortuem, MD, Chang-Xin Shi, PhD, Jessica Schmidt, David Craig, PhD, John Carpten, PhD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 3968.

https://doi.org/10.1182/blood.V120.21.3968.3968

Published: 2012

Journal Articles

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

Jan B. Egan, Chang-Xin Shi, Waibhav Tembe, Alexis Christoforides, Ahmet Kurdoglu, Shripad Sinari, Sumit Middha, Yan Asmann, Jessica Schmidt, Esteban Braggio, Jonathan J. Keats, Rafael Fonseca, P. Leif Bergsagel, David W. Craig, John D. Carpten, A. Keith Stewart

Blood (2012) 120 (5): 1060–1066.

https://doi.org/10.1182/blood-2012-01-405977

Published: 2012

Includes: Supplemental data

Journal Articles

Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide

Yuan Xiao Zhu, PhD, Esteban Braggio, PhD, Chang-Xin Shi, PhD, Jessica Schmidt, Laura Bruins, Steven R. Schuster, MD, Rafael Fonseca, MD, P. Leif Bergsagel, MD, Chad C. Bjorklund, Ph.D., Robert Z. Orlowski, MD, PhD, A. Keith Stewart, MD

Blood (2011) 118 (21): 127.

https://doi.org/10.1182/blood.V118.21.127.127

Published: 2011

Journal Articles

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6

Rodger E. Tiedemann, Yuan Xiao Zhu, Jessica Schmidt, Hongwei Yin, Chang-Xin Shi, Qiang Que, Gargi Basu, David Azorsa, Louise M. Perkins, Esteban Braggio, Rafael Fonseca, P. Leif Bergsagel, Spyro Mousses, A. Keith Stewart

Blood (2010) 115 (8): 1594–1604.

https://doi.org/10.1182/blood-2009-09-243980

Published: 2010

Includes: Supplemental data

Journal Articles

Kinome-Wide RNAi Studies in Human Multiple Myeloma Identify a Lymphoid Restricted Kinase GRK6 as a Selectively Vulnerable Target That Regulates STAT3/MCL1.

Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Yuan Xiao Zhu, Jessica Schmidt, BS, Hongwei Yin, PhD, Quick Que, PhD, David Azorsa, PhD, Louise M. Perkins, PhD, Esteban Braggio, PhD, Craig B. Reeder, MD, Rafael Fonseca, MD, P. Leif Bergsagel, MD, Spyro Mousses, PhD, A. Keith Stewart, MD

Blood (2009) 114 (22): 601.

https://doi.org/10.1182/blood.V114.22.601.601

Published: 2009

Journal Articles

RNAi Screen of the Druggable Genome Identifies Modulators of Proteasome Inhibitor Sensitivity in Myeloma Including CDK5.

Yuan Xiao Zhu, PhD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Chang-Xin Shi, PhD, Jessica Schmidt, BS, Laura Bruins, Jonathan J Keats, PhD, Holly Yin, PhD, Chris Sereduk, Spyro Mousses, PhD, A. Keith Stewart, MBChB

Blood (2009) 114 (22): 602.

https://doi.org/10.1182/blood.V114.22.602.602

Published: 2009

Journal Articles

Achilles Heel Molecular Vulnerabilities in Multiple Myeloma Identified From Genome-Scale RNA Interference Screening.

Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Yuan Xiao Zhu, Jessica Schmidt, BS, Chang-Xin Shi, Hongwei Yin, PhD, Spyro Mousses, PhD, A. Keith Stewart, MD

Blood (2009) 114 (22): 2801.

https://doi.org/10.1182/blood.V114.22.2801.2801

Published: 2009

Journal Articles

Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-κB with antimyeloma activity in vitro and in vivo

Rodger E. Tiedemann, Jessica Schmidt, Jonathan J. Keats, Chang-Xin Shi, Yuan Xiao Zhu, Stephen E. Palmer, Xinliang Mao, Aaron D. Schimmer, A. Keith Stewart

Blood (2009) 113 (17): 4027–4037.

https://doi.org/10.1182/blood-2008-09-179796

Published: 2009

Includes: Supplemental data

Journal Articles

Identification of a Potent Natural Triterpenoid Inhibitor of Proteosome Chymotrypsin-Like Activity and NF-κB with Specific Anti-Myeloma Activity in Vitr o and in Vivo

Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Jonathan J Keats, PhD, Jessica Schmidt, BS, Chang-Xin Shi, Yuan X Zhu, PhD, Xinliang Mao, MD, PhD, Aaron D. Schimmer, Keith Stewart, MD

Blood (2008) 112 (11): 3679.

https://doi.org/10.1182/blood.V112.11.3679.3679

Published: 2008

NARROW

A Synthetic Lethality Druggable Genome RNAi Screen Identifies Genes Mediating Sensitivity To Lenalidomide In Multiple Myeloma Including RSK2

Development Of a 47 Gene Sequencing Panel For Common Mutations Present In Multiple Myeloma : Preliminary Results In 77 p53 Deleted Patients

Cereblon Binding IMiD Small Molecules Mediate Myeloma Cell Death Via IRF4

Genome Wide Studies in Multiple Myeloma Identify XPO1/CRM-1 As a Critical Target Validated Using the Selective Inhibitor of Nuclear Export (SINE) KPT-276

Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma

The Myeloma Genome in Drug Refractory Extra-Medullary Disease Identifies Mutations in Proteasome, Cereblon and Glucocorticoid Pathways

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6

Kinome-Wide RNAi Studies in Human Multiple Myeloma Identify a Lymphoid Restricted Kinase GRK6 as a Selectively Vulnerable Target That Regulates STAT3/MCL1.

RNAi Screen of the Druggable Genome Identifies Modulators of Proteasome Inhibitor Sensitivity in Myeloma Including CDK5.

Achilles Heel Molecular Vulnerabilities in Multiple Myeloma Identified From Genome-Scale RNA Interference Screening.

Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-κB with antimyeloma activity in vitro and in vivo

Identification of a Potent Natural Triterpenoid Inhibitor of Proteosome Chymotrypsin-Like Activity and NF-κB with Specific Anti-Myeloma Activity in Vitr o and in Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only